NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

William J Gradishar,Kilian E Salerno,Hatem Soliman,P Kelly Marcom,Mary Lou Smith,Beryl Mccormick,Andres Forero,Amy Cyr,Sameer A Patel,Rashmi Kumar,Ingrid A Mayer,Lee S Schwartzberg,Dorothy A Shead,Steven J Isakoff,Sarah L Blair,Lori J Pierce,William B Farrar,Matthew P Goetz,Meena S Moran,Lori J Goldstein,Benjamin O Anderson,Harold J Burstein,John H Ward,George Somlo,Janice A Lyons ,Amy M Sitapati ,Sharon H Giordano ,Ruth O’regan ,Elizabeth Reed ,Anthony Elias ,Melinda L Telli ,Ronald Balassanian ,Karen L Smith

doi:10.6004/jnccn.2017.0044

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

William J Gradishar, Kilian E Salerno + Show 31 more

Open Access

https://doi.org/10.6004/jnccn.2017.0044

Copy DOI

Journal: Journal of the National Comprehensive Cancer Network	Publication Date: Apr 1, 2017
Citations: 338

Affiliation: Roswell Park Cancer Institute, University of South Florida, Cancer Institute (WIA), Research Advocacy Network, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, Washington University in St. Louis, Fox Chase Cancer Center, Vanderbilt University, St. Jude Children's Research Hospital, Harvard University Press, University of California, San Diego, University of Michigan–Ann Arbor, The Ohio State University, Mayo Clinic, Yale Cancer Center, Seattle Cancer Care Alliance, Dana-Farber Brigham Cancer Center, University of Utah, City Of Hope National Medical Center, Case Western Reserve University, The University of Texas MD Anderson Cancer Center, Susan Thompson Buffett Foundation, University of Colorado System, University of Colorado Boulder, Stanford University, University of California, San Francisco, Johns Hopkins University

#NCCN Guidelines For Breast Cancer #Version Of Guidelines + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of the National Comprehensive Cancer Network

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.